Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
The present invention relates to new pyrrolopyridine compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibition of JAK1 and JAK3 kinase activity in a human or animal subject are also provided for the treatment diseases such as pruritus, alopecia, androgenetic alopecia, alopecia areata, vitiligo and psoriasis.
1. A compound, or a pharmaceutically acceptable salt, hydrate or solvate thereof, of Formula (I):
wherein:
R 1 is —CO 2 R 5 ;
R 2 is H;
n is 1 or 2;
Ring A is substituted with one R 3 substituents wherein R 3 is selected from H or —C 1 -C 4 alkyl;
R 4 is —C(O)—C 1 -C 5 alkyl, wherein the alkyl groups may be optionally substituted with —CN; and
R 5 is —C 1 -C 5 alkyl.
2. The compound of claim 1 , wherein the compound is:
ethyl 4-(((3R,4R)-1-(2-cyanoacetyl)-4-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate.
3. The compound of claim 1 , wherein the compound is:
ethyl (R)-4-((1-(2-cyanoacetyl)piperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate.
4. The compound of claim 1 , wherein the compound is:
ethyl 4-(((3R,6S)-1-(2-cyanoacetyl)-6-methylpiperidin-3-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxylate.
5. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , a pharmaceutically acceptable salt thereof, a derivative thereof, or a combination thereof; and a pharmaceutically acceptable carrier.